JAK2/STAT3/HMGCS2 signaling aggravates mitochondrial dysfunction and oxidative stress in hyperuricemia-induced cardiac dysfunction

• Published in: Molecular medicine (Cambridge, Mass.) Vol. 31; no. 1; pp. 184 - 23
• Main Authors: Peng, Dewei, He, Xiaoli, Ren, Bowen, Wang, Qian, Peng, Lulu, Jiang, Yue, Huo, Shengqi, Men, Lintong, Shi, Wei, Luo, Pengcheng, Zhu, Mengyin, Zhang, Cuntai, Lv, Jiagao, Lin, Li, Li, Sheng
• Format: Journal Article
• Language: English
• Published: England BioMed Central 13.05.2025; BMC
• Subjects: Animals; Cardiac dysfunction; Disease Models, Animal; Heart Diseases - etiology; Heart Diseases - metabolism; HMGCS2; Hyperuricemia; Hyperuricemia - complications; Hyperuricemia - metabolism; JAK2; Janus Kinase 2 - metabolism; Male; Mice; Mice, Inbred C57BL; Mitochondria - metabolism; Mitochondrial function; Myocytes, Cardiac - metabolism; Oxidative Stress; Signal Transduction; STAT3; STAT3 Transcription Factor - genetics; STAT3 Transcription Factor - metabolism; Uric Acid; Hyperuricemia; HMGCS2; JAK2; Mitochondrial function; Cardiac dysfunction; STAT3
• ISSN: 1528-3658; 1076-1551; 1528-3658
• DOI: 10.1186/s10020-025-01246-x

High uric acid levels play a critical role in cardiovascular disease pathophysiology, being closely linked to their occurrence, progression, and prognosis. To enhance prevention and treatment of hyperuricemia-related cardiovascular diseases, understanding underlying mechanisms and identifying novel therapeutic targets are essential. A hyperuricemic mouse model was established, and transcriptomic analysis of myocardial tissue was conducted using RNA sequencing. The role of HMGCS2 in hyperuricemia-induced cardiomyocytes was investigated through HMGCS2 knockout. The transcriptional regulation of HMGCS2 by STAT3 was explored via STAT3 knockdown, overexpression, and dual-luciferase reporter assays. To further elucidate the role of the JAK2/STAT3/hmgcs2 signaling pathway in hyperuricemia-induced cardiomyocytes, we overexpressed HMGCS2 while intervening in the JAK2/STAT3 pathway in vitro. The therapeutic potential of targeting the JAK2/STAT3/HMGCS2 pathway was evaluated in hyperuricemic mice using STAT3 and JAK inhibitors to assess effects on cardiac dysfunction. RNA sequencing showed significant upregulation of HMGCS2 mRNA in hyperuricemic mouse cardiac tissue. Increased HMGCS2 protein levels were observed in cardiac tissue and AC16 cardiomyocytes. HMGCS2 knockdown alleviated uric acid-induced mitochondrial dysfunction, oxidative stress, and abnormal energy metabolism in AC16 cardiomyocytes. And high uric acid levels activate the IL-6/JAK2/STAT3 signaling pathway in AC16 cardiomyocytes, which regulates HMGCS2 expression. By modulating JAK2 and STAT3 expression and subsequently overexpressing HMGCS2, we identified the involvement of the JAK2/STAT3/HMGCS2 pathway in uric acid-induced mitochondrial dysfunction, oxidative stress, and energy metabolism abnormalities in AC16 cardiomyocytes. In vitro experiments demonstrated that intervention with the ruxolitinib and S3I-201 could ameliorate mitochondrial dysfunction, oxidative stress, and ATP levels in the heart tissue of hyperuricemic mice. Moreover, these treatments also reversed cardiac function abnormalities. The JAK2/STAT3/HMGCS2 pathway may contributes to uric acid-induced cardiac dysfunction by affecting mitochondrial function, oxidative stress, and ATP metabolism, offering a potential therapeutic strategy for mitigating high uric acid-induced cardiac damage.